New Study Provides Comparative Analysis Of Twelve COVID-19 V
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A new study provides a comparative analysis of twelve COVID-19 Vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global COVID-19 pandemic.

~ COVID-19 vaccines analyzed for the study:

• messenger RNA - Moderna and Pfizer/BioNtech

• Viral Vector-based (non-replicating) Vaccines - Astra Zeneca/University of Oxford, CanSino Biologics, Gamaleya Research Institute, Johnson & Johnson/Janssen (J&J))

• Recombinant Protein-based Vaccines - Novavax and Medicago

• Inactivated Virus - Three Chinese conglomerates and one Indian company

COVID-19 Vaccines belonging to four different platforms were analyzed in five different categories using a harmonized target product profile (TPP) version of guidance from the World Health Organization, Coalition for Epidemic Preparedness Innovations (CEPI) and Center for Biologics Evaluation and Research (CBER). Key analysis from the study -

• Vaccine Efficacy - mRNA vaccines were a clear winner with efficacy in the 95% range and across a spectrum of ages, followed by the protein subunit platform with an efficacy of just under 90% in the UK. The inactivated virus platform ranks lowest based on currently available variable data.

• Dosing regimen - All but two (CanSino and Johnson & Johnson/Janssen) of the 12 vaccines in the various platforms analyzed in this study use a two-dose regimen.

• Logistics - mRNA vaccines rank lowest with their burdensome cold-chain requirements.

• Safety/reactogenicity - The inactivated virus platform was the top performer. The viral vector platform scores below the other three platforms due to some lingering concerns related to paused trials and adverse events.

• Target price/accessibility - The production of mRNA vaccines can be scaled-up at a reasonable pace, but they are currently among the most expensive COVID-19 vaccines; the viral vector vaccines are the cheapest to prepare. The inactivated virus vaccines are relatively easy to produce and are cheap if one considers Bharat Biotech's COVAXIN.

The study has also identified three main barriers/hurdles for ending the global COVID-19 pandemic -

While we know that antibody levels induced by natural infection with SARS-CoV-2 last several months, we do not know if there will be a requirement for repeat vaccine dosing on an annual (or other timeframe) basis. If repeat booster doses are required, especially related to the viral vector platform, will antibodies be directed to the vector and will this diminish vaccine efficacy?

Determining an immunological correlate of protection against SARS-CoV-2 is an important objective that still has not been achieved and will be crucial in facilitating future COVID-19 vaccine development and licensing.

Public perception and compliance in vaccine administration are also very large hurdles to surmount in order to achieve herd immunity in some countries/populations. While not discussed in this review, this is a key point that cannot be overlooked.

Source:
https://www.mdpi.com/1999-4915/13/3/418
s●●●i p●●●a and 5 others like this4 shares
Like
Comment
Share